Reuters logo
5 months ago
BRIEF-GenSight Biologics completes enrollment of reverse phase III study of GS010
February 21, 2017 / 6:44 AM / 5 months ago

BRIEF-GenSight Biologics completes enrollment of reverse phase III study of GS010

1 Min Read

Feb 21 (Reuters) - GenSight Biologics SA:

* Completes enrollment of reverse phase III study of GS010 in the treatment of Leber's Hereditary Optic Neuropathy (LHON)

* Topline results of reverse at 48 weeks are expected at end of Q1 2018

* Rescue is expected to complete enrollment by end of H1 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below